| Place of Origin: | China |
|---|---|
| Brand Name: | HNB |
| Certification: | ISO |
| Model Number: | HNB-Ribavirin |
| Minimum Order Quantity: | 1KG |
| Price: | Negotiable |
| Packaging Details: | Aluminum foil bag |
| Delivery Time: | Usually7-10days |
| Payment Terms: | L/C, D/A, D/P, T/T, , MoneyGram |
| Supply Ability: | 5000kg/Month |
| CAS: | 36791-04-5 | Mf: | C8H12N4O5 |
|---|---|---|---|
| MW: | 244.205 | Specification: | ≥98% |
| Appearance: | White Powder | Purity: | 99%,99%min |
| Shelf Life: | 2 Years | Grade: | Medical Grade,Phamaceutical Grade,Medicine & Tech,USP BP FCC EP |
| High Light: | Ribavirin Antiviral Agent,Pharmaceutical API CAS 36791-04-5,Pharmaceutical AP Ribavirin Powder |
||
CAS 36791-04-5 Pharmaceutical API Ribavirin antiviral agent
| Product Name: | Ribavirin |
| Synonyms: |
Rebetol |
| CAS: | 36791-04-5 |
| MF: | C8H12N4O5 |
| MW: | 244.205 |
The Introductction
Ribavirin is a broad-spectrum antiviral that inhibits HCV, HIVl, RSV, and other viruses.
1. Ribavirin is phosphorylated in red blood cells to produce ribavirin monophosphate, diphosphate and triphosphate. Among them, riboside monophosphate is a strong inhibitory preparation of inosine monophosphate dehydrogenase, which can inhibit the synthesis of cell guanylate, reduce cell guanylate triphosphorylation, and block the synthesis of viral nucleic acid.
2. Riboside triphosphate inhibits influenza virus RNA polymerase and interferes with viral replication.
3. Riboside triphosphate inhibits the synthesis and transcriptase of the 5 'terminal of viral Mrna, thereby inhibiting DNA and RNA synthesis. It can inhibit a variety of viruses (including DNA viruses and RNA viruses). It is effective against influenza, adenovirus pneumonia, hepatitis A, herpes, measles, and epidemic hemorrhagic fever.
4. It is mainly excreted in the urine in its original form, with a small amount of deglucosed riboside metabolites and a small amount excreted from the stool.
The Application & Function
Ribavirin indication
In vitro, Ribavirin can inhibit the growth of respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus and other viruses, but its mechanism is not fully clear. This product does not change virus adsorption, invasion and molting, nor does it induce interferon production. After entering virus-infected cells, the drug is phosphorylated rapidly, and its product acts as a competitive inhibitor of viral synthetase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing the reduction of intracellular guanosine triphosphate, damaging viral RNA and protein synthesis, and inhibiting viral replication and transmission. Respiratory syncytial virus may also have immune and neutralizing antibody effect.
1. For the treatment of Lassa fever or epidemic hemorrhagic fever (with renal syndrome or pneumonia) (intravenous or oral).
2, for the treatment of chronic hepatitis C (combined with recombinant interferon alpha 2b or peg interferon alpha).
3, prevention and treatment of viral upper respiratory tract infection (nasal drops).
The COA
| Item | Specification | Results |
| APPEARANCE | WHITE | CONFORMS |
| SOLUBILITY | FREELY SOLUBLE IN CHLOROFORM;SOLUBLE IN WATER OR METHANOL; | CONFORMS |
| PH | 5.0-7.2 | 6.51 |
| LOSS ON DRYING | ≤4.5% | 3.10% |
| RESIDUEON IGNITION | ≤2.5% | 0.281% |
| HEAVY METALS | ≤20PPM | <15PPM |
| TYRAMINE | ≤0.35% | 0.051% |
| RELATED COMPOSITIONS | TYLOSIN A ≥80% A+B+C+D ≥95% | 93% 98% |
| Conclusion | Confirm with the standard |